Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Bioequivalence Study of Enalapril Tablet to $Lenipril^{(R)}$ Tablet

레니프릴정(에날라프릴 10 mg)에 대한 에날라프릴정의 생물학적 동등성 평가

  • 노금한 (대구가톨릭대학교 약학대학 임상약학 연구실) ;
  • 배경진 (대구가톨릭대학교 약학대학 임상약학 연구실) ;
  • 강원구 (대구가톨릭대학교 약학대학 임상약학 연구실)
  • Received : 2009.04.06
  • Accepted : 2009.05.23
  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The study was designed to compare the rate and extent of absorption of two enalapril tablets (10 mg), which has been widely used for the treatment of hypertension. This bioequivalence study was conducted using a standard preparation as reference and a generic as test in 24 male healthy volunteers. After an overnight fast, a single dose of the test or reference drugs were given with a washout period of 7 days. Heparinized blood samples were serially collected up to 10 hr. Plasma enalapril concentrations were quantified using a validated LC-MS/MS method. The data obtained for each subject was evaluated for $C_{max}$ and $AUC_{10hr}$ with respect to 90% confidence interval for log-transformed data. The 90% confidence intervals were log(0.9384)~log(1.1160) for $AUC_{10hr}$ and log(0.9482)~log(1.1474) for $C_{max}$. Thus, we concluded that the test and reference formulation are bioequivalent in terms of rate and extent of absorption.

Keywords

References

  1. Pang KS, Cherry WF, Terrell JA et al. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metab Dispos. 1984; 12(3): 309-313.
  2. Peter AT, Rennie CH. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986; 31: 198-24 https://doi.org/10.2165/00003495-198631030-00002
  3. Rorbert JM, Peter AM, Henry LE. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Clin. Pharmacokinet. 1993; 25: 274-282 https://doi.org/10.2165/00003088-199325040-00003
  4. 식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험 기준 (2002. 11. 22)
  5. Tikkanen FF, Gronhagen-Riska C. Competitive inhibitor binding assay (IBA) of captopril and ther inhibitors of angiotensin converting enzyme. Scand. J. Uro.l Nephro.l Suppl. 1984; 79: 13-16.
  6. Matalka K, Arafat T, Hamad M et al. Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. Fundam. Clin. Pharmacol. 2002; 16(3): 237-244. https://doi.org/10.1046/j.1472-8206.2002.00087.x
  7. Shepley K, Rocci ML Jr, Patrick H et al. An optimized fluoroenzymatic assay for the determination of angiotensin converting enzyme inhibitors in biological fluids. J. Pharm. Biomed. Anal. 1988; 6(3): 241-251. https://doi.org/10.1016/0731-7085(88)80050-5
  8. Lee J, Son J, Lee M et al. Simultaneous quantitation of enalapril and enalaprilat in human plasma by 96-well solid-phase extraction and liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2003; 17(11): 1157-1162. https://doi.org/10.1002/rcm.1040
  9. Lu S, Jiang K, Qin F et al. Simultaneous quantification of enalapril and enalaprilat in human lasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. J. Pharm. Biomed. Anal. 2009; 49(1): 163-167. https://doi.org/10.1016/j.jpba.2008.10.012